First Trust Direct Indexing’s Cardinal Health CAH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-9,863
Closed -$1.09M 137
2024
Q3
$1.09M Sell
9,863
-2,062
-17% -$216K 0.06% 325
2024
Q2
$1.17M Buy
11,925
+426
+4% +$43.4K 0.07% 280
2024
Q1
$1.29M Buy
11,499
+601
+6% +$64.8K 0.1% 238
2023
Q4
$1.1M Buy
10,898
+908
+9% +$90.1K 0.1% 238
2023
Q3
$867K Sell
9,990
-27
-0.3% -$2.44K 0.1% 237
2023
Q2
$947K Sell
10,017
-800
-7% -$67.6K 0.11% 223
2023
Q1
$817K Buy
10,817
+1,163
+12% +$87.7K 0.1% 264
2022
Q4
$742K Buy
9,654
+107
+1% +$8.13K 0.1% 274
2022
Q3
$637K Buy
9,547
+810
+9% +$51.3K 0.09% 285
2022
Q2
$457K Buy
8,737
+940
+12% +$53.4K 0.06% 371
2022
Q1
$442K Buy
7,797
+379
+5% +$20.3K 0.05% 402
2021
Q4
$382K Buy
7,418
+1,033
+16% +$50.7K 0.05% 429
2021
Q3
$316K Sell
6,385
-1,001
-14% -$54.3K 0.04% 462
2021
Q2
$422K Buy
7,386
+2,985
+68% +$174K 0.06% 363
2021
Q1
$267K Sell
4,401
-1,292
-23% -$71.3K 0.07% 327
2020
Q4
$305K Buy
+5,693
New +$295K 0.08% 283

Other funds holding CAH

First Trust Direct Indexing's CAH Position: Q4 2024 in Review

First Trust Direct Indexing sold out of Cardinal Health (CAH) in Q4 2024, closing a stake of 9,863 shares — an estimated $1.09M sold.

First Trust Direct Indexing first reported a position in CAH in Q4 2020 and held it in 16 quarters. The position peaked at $1.29M in Q1 2024. 1,097 funds tracked by Wall St. Rank hold CAH as of Q4 2024.

  • First Trust Direct Indexing reported no remaining Cardinal Health position as of Q4 2024 after selling out during the quarter.
  • First Trust Direct Indexing sold 9,863 Cardinal Health shares in Q4 2024, an estimated $1.09M.
  • First Trust Direct Indexing first reported a position in Cardinal Health in Q4 2020 and held it in 16 quarters.
  • First Trust Direct Indexing's Cardinal Health position peaked at $1.29M in Q1 2024.
  • 1,097 funds tracked by Wall St. Rank held Cardinal Health as of Q4 2024.

Based on First Trust Direct Indexing's 13F filing for Q4 2024.